Trial Profile
A phase II trial to assess daclatasvir, in combination with asunaprevir, and asunaprevir/beclabuvir/daclatasvir in patients co-infected with genotype 1 hepatitis C, and HIV, who are naive to directly-acting antivirals and are receiving antiretrovirals
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Asunaprevir/becabluvir/daclatasvir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CONQUER
- 20 Aug 2015 New trial record